Mizuho Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $114
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has maintained a Neutral rating on Neurocrine Biosciences (NASDAQ:NBIX) but has lowered the price target from $116 to $114.
November 10, 2023 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho has maintained a Neutral rating on Neurocrine Biosciences and reduced the price target from $116 to $114.
The adjustment in price target by Mizuho is a minor change, suggesting a slight decrease in expected performance but not a change in overall sentiment. The Neutral rating remains unchanged, indicating that Mizuho does not see significant upside or downside in the near term. This news is likely to have a limited impact on the stock price as it does not suggest a major shift in market position or performance expectations.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100